Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/80033
Title:
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Authors:
Paul, M J; Summers, Yvonne J; Calvert, A Hilary; Rustin, G J; Brampton, M; Thatcher, Nick; Middleton, Mark R
Abstract:
Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS). Isolated CNS relapse is increasingly a problem for patients who respond to biochemotherapy. By replacing DTIC with temozolomide in treatment regimens, the incidence of CNS relapse might be reduced. This hypothesis is difficult to test in a prospective randomized controlled trial because of the large number of patients that would be required. We have examined this question in a retrospective case control study, observing the rates of CNS relapse in advanced metastatic melanoma patients responding to DTIC- or temozolomide-based chemotherapy in three institutions. Twenty-one DTIC and 20 temozolomide responders were identified, and have been followed up for a median of 19.0 months (range 6.0-74.3 months). CNS relapse occurred in nine DTIC- and two temozolomide-treated patients, a statistically significant difference in favour of the new agent (P = 0.03). These results support the investigation of temozolomide as a replacement for DTIC in systemic treatment regimens for melanoma.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. 2002, 12 (2):175-8 Melanoma Res.
Journal:
Melanoma Research
Issue Date:
Apr-2002
URI:
http://hdl.handle.net/10541/80033
PubMed ID:
11930115
Type:
Article
Language:
en
ISSN:
0960-8931
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPaul, M J-
dc.contributor.authorSummers, Yvonne J-
dc.contributor.authorCalvert, A Hilary-
dc.contributor.authorRustin, G J-
dc.contributor.authorBrampton, M-
dc.contributor.authorThatcher, Nick-
dc.contributor.authorMiddleton, Mark R-
dc.date.accessioned2009-09-07T12:38:24Z-
dc.date.available2009-09-07T12:38:24Z-
dc.date.issued2002-04-
dc.identifier.citationEffect of temozolomide on central nervous system relapse in patients with advanced melanoma. 2002, 12 (2):175-8 Melanoma Res.en
dc.identifier.issn0960-8931-
dc.identifier.pmid11930115-
dc.identifier.urihttp://hdl.handle.net/10541/80033-
dc.description.abstractTemozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS). Isolated CNS relapse is increasingly a problem for patients who respond to biochemotherapy. By replacing DTIC with temozolomide in treatment regimens, the incidence of CNS relapse might be reduced. This hypothesis is difficult to test in a prospective randomized controlled trial because of the large number of patients that would be required. We have examined this question in a retrospective case control study, observing the rates of CNS relapse in advanced metastatic melanoma patients responding to DTIC- or temozolomide-based chemotherapy in three institutions. Twenty-one DTIC and 20 temozolomide responders were identified, and have been followed up for a median of 19.0 months (range 6.0-74.3 months). CNS relapse occurred in nine DTIC- and two temozolomide-treated patients, a statistically significant difference in favour of the new agent (P = 0.03). These results support the investigation of temozolomide as a replacement for DTIC in systemic treatment regimens for melanoma.en
dc.language.isoenen
dc.subjectBrain Canceren
dc.subjectLung Canceren
dc.subjectCancer Recurrenceen
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents, Alkylating-
dc.subject.meshBrain Neoplasms-
dc.subject.meshCase-Control Studies-
dc.subject.meshDacarbazine-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMelanoma-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshNeoplasm Staging-
dc.subject.meshRetrospective Studies-
dc.subject.meshSoft Tissue Neoplasms-
dc.subject.meshSurvival Rate-
dc.subject.meshTreatment Outcome-
dc.titleEffect of temozolomide on central nervous system relapse in patients with advanced melanoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalMelanoma Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.